| Literature DB >> 3354029 |
S C Fagan1, F M Gengo, V Bates, S R Levine, W R Kinkel.
Abstract
Nimodipine is currently under investigation for the treatment of acute stroke. Although relatively specific for the cerebrovasculature, acute reductions in blood pressure after a dose may adversely affect neurologic outcome. We studied 29 consecutive acute ischemic stroke patients treated with placebo (n = 9) or either 120 (n = 10) or 240 (n = 10) mg/day of nimodipine. Blood pressure was recorded before and 30 and 60 minutes after a dose for the first 8 days. Ten neurologic physicians were asked to predict the treatment group (placebo or drug) of randomly selected patients based on blood pressure results. Only those patients on 240 mg/day of nimodipine had significant decreases in blood pressure after a dose (p less than 0.001); however, these were minimal (average 10 mm Hg systolic). Only 26 of 48 treatment predictions (54%) were correct. At the studied doses, nimodipine has a minimal effect on blood pressure in the acute stroke period.Entities:
Mesh:
Substances:
Year: 1988 PMID: 3354029 DOI: 10.1161/01.str.19.3.401
Source DB: PubMed Journal: Stroke ISSN: 0039-2499 Impact factor: 7.914